Healthcare has spent months watching technology and financials dominate the conversation.
Now the sector gets its own earnings test. Drug demand, surgical procedures, insurance costs, and medical-device growth will show whether healthcare can deliver the defensive growth investors keep looking for.
Growth Picks (Sponsored)
Many investors are seeing solid gains in today’s market, but solid gains often hide opportunities with far greater potential.
A new analysis highlights the 5 Stocks Set to Double, selected from thousands of companies showing early signs of powerful growth.
These picks feature strong fundamentals and technical indicators that often appear before meaningful upside.
Past editions of this research uncovered gains of +175%, +498%, and +673%.
Download the 5 Stocks Set to Double. Free Today.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Theme: Pharmaceuticals, Medical Devices, Managed Care, Procedure Volumes, and Defensive Growth
This setup works because healthcare has more than one engine.
Patients still need treatment when the economy slows. Hospitals still perform procedures. Insurers still collect premiums and manage medical costs. Pharmaceutical companies can keep growing when newer drugs replace older blockbusters. Device makers benefit when procedure volumes rise and new technology expands what doctors can treat.
That gives healthcare a useful mix of defense and growth.
Johnson & Johnson reports Wednesday. UnitedHealth and Intuitive Surgical follow Thursday. Together, those updates give investors a broad read on medicines, medical technology, insurance costs, healthcare services, and surgical demand.
The market is not looking for a simple “healthcare is defensive” story. It wants proof that the sector can still grow.
What’s Driving It
The latest results have been strong across several parts of the group.
Johnson & Johnson reported first-quarter sales of $24.1 billion, up 9.9%, and raised its full-year outlook. Its portfolio gives investors exposure to oncology, immunology, neuroscience, cardiovascular products, surgery, and vision.
UnitedHealth reported first-quarter revenue of $111.7 billion, adjusted earnings of $7.23 per share, and raised its full-year adjusted earnings outlook. The key question this quarter is whether insurance pricing and operational improvements are keeping pace with medical utilization.
Intuitive Surgical remains one of the clearest procedure-growth stories in the market. First-quarter revenue rose 23% to $2.77 billion. Worldwide da Vinci and Ion procedures increased roughly 17%, while the da Vinci installed base grew 12%.
Boston Scientific reported first-quarter sales of $5.2 billion, up 11.6%, with cardiovascular sales rising 13.5%. AbbVie reported revenue of $15.0 billion, up 12.4%, as Skyrizi, Rinvoq, neuroscience products, and Botox helped offset the continued decline in Humira.
Here is the chain reaction:
Healthcare earnings arrive → medical demand gets tested
Procedure volumes hold → device companies keep growing
New medicines gain share → pharma replaces older products
Insurance pricing catches up → managed-care margins stabilize
Investors seek durable earnings → healthcare regains attention
What’s Working
What is working now is innovation tied to recurring demand.
J&J and AbbVie are replacing older products with newer medicines that are still taking share. Intuitive and Boston Scientific benefit when doctors adopt technology that expands treatment options and improves procedures. UnitedHealth gets paid through both insurance and healthcare services.
The device companies may offer the cleanest growth. Procedure demand is rising, installed bases are expanding, and recurring revenue follows each new system or device placement.
The pharmaceutical names bring more cash flow and diversification. The managed-care angle carries more controversy and uncertainty, but it can also offer more recovery upside if medical costs stabilize.
This is not one healthcare trade. It is several different businesses tied together by demand that rarely disappears.
What to Watch
You should watch Johnson & Johnson’s Innovative Medicine growth, MedTech sales, UnitedHealth’s medical-care ratio, Optum performance, insurance membership, Intuitive’s procedure growth, system placements, cardiovascular-device demand, drug pipelines, and full-year guidance.
The biggest risk is cost pressure. Hospitals, insurers, and device makers still face higher labor, supply, and operating costs.
The second risk is policy. Drug pricing, insurance regulation, reimbursement, and healthcare reform can change investor sentiment quickly.
For the faster-growing device names, valuation remains the pressure point. Strong growth is already expected, so clean results may not be enough if guidance looks ordinary.
Johnson & Johnson (JNJ)
What it does:
Johnson & Johnson develops medicines and medical technologies across oncology, immunology, neuroscience, cardiovascular care, surgery, orthopedics, and vision.
Why it fits:
J&J is the direct earnings catalyst and the quality anchor in the basket. First-quarter sales rose 9.9% to $24.1 billion, and management raised its 2026 guidance.
What stands out:
This is the broadest healthcare stock in the group. J&J combines pharmaceutical growth with medical-device exposure, giving it more than one way to benefit from medical demand.
What to watch:
Watch oncology and immunology growth, MedTech sales, cardiovascular momentum, procedure volumes, margins, talc litigation, and updated guidance.
The Takeaway: Buy this first if you want the most diversified healthcare stock tied directly to this week’s earnings.
The risk is that legal liabilities or slower MedTech growth overshadow otherwise steady operating results.
UnitedHealth Group (UNH)
What it does:
UnitedHealth operates UnitedHealthcare insurance plans and Optum healthcare services, as well as pharmacy benefit, care delivery, and technology businesses.
Why it fits:
UnitedHealth is the managed-care recovery name. First-quarter revenue rose to $111.7 billion, adjusted earnings reached $7.23 per share, and management raised its full-year outlook.
What stands out:
This is the highest-stakes report in the basket. The market wants evidence that medical costs, insurance pricing, Optum performance, and operational changes are moving in the right direction.
What to watch:
Watch the medical-care ratio, Medicare Advantage utilization, pricing, membership, Optum revenue, operating margins, cash flow, and guidance.
The Takeaway: Buy this only if you want the healthcare recovery trade with the most rerating potential.
The risk is that medical costs remain higher than expected and force another reset in earnings assumptions.
Top Picks (Sponsored)
Only a tiny percentage of stocks meet the criteria for this report.
Analysts have released a new edition highlighting seven names selected using multiple indicators.
Recent picks have delivered notable short-term gains, though results can vary.
The latest report is now available for a limited time.
Download the free report today.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Intuitive Surgical (ISRG)
What it does:
Intuitive Surgical develops robotic surgical systems, instruments, accessories, software, and diagnostic platforms through da Vinci and Ion.
Why it fits:
Intuitive is the procedure-growth leader. First-quarter revenue rose 23%, combined worldwide procedures grew around 17%, and the company expanded both its da Vinci and Ion installed bases.
What stands out:
This is the recurring-revenue growth name. Each additional system creates demand for instruments, accessories, service, and future procedures.
What to watch:
Watch da Vinci procedure growth, Ion growth, da Vinci 5 placements, system leasing, recurring revenue, gross margin, tariffs, and full-year procedure guidance.
The Takeaway: Buy this if you want the highest-quality medical-device compounder tied to robotic surgery.
The risk is valuation. Intuitive needs sustained double-digit procedure growth to justify its premium.
Boston Scientific (BSX)
What it does:
Boston Scientific develops medical devices used in cardiology, electrophysiology, endoscopy, urology, neuromodulation, and other minimally invasive procedures.
Why it fits:
Boston Scientific gives the basket faster-growing cardiovascular and procedural exposure. First-quarter sales rose 11.6%, while cardiovascular sales increased 13.5%.
What stands out:
This is the device-growth name with a broad pipeline. Boston Scientific benefits from structural demand in electrophysiology, structural heart, endoscopy, and minimally invasive treatment.
What to watch:
Watch cardiovascular growth, electrophysiology, Watchman demand, organic sales, procedure trends, product launches, and margin performance.
The Takeaway: Buy this if you want broad medical-device growth with more product diversification than a single-platform company.
The risk is that investors have high expectations for its fastest-growing franchises, leaving little room for product-level disappointment.
Six months (Sponsored)
Whitney Tilson has built a reputation for identifying major market turning points before they become widely recognized.
Now, he believes the next six months could mark the beginning of a significant shift for both the economy and investors.
In his latest free presentation, he explains what's driving his outlook, the steps he believes investors should consider, and the opportunity he says could outperform traditional assets in the years ahead.
Watch the Free Presentation
AI infrastructure vs. AI applications — where are you placing your bets?
AbbVie (ABBV)
What it does:
AbbVie develops medicines across immunology, neuroscience, oncology, aesthetics, and eye care.
Why it fits:
AbbVie is the pharmaceutical replacement story. First-quarter revenue rose 12.4% to $15.0 billion, with Skyrizi revenue up 30.9% and Rinvoq up 23.3%.
What stands out:
This is the proof that a large pharmaceutical company can move beyond a fading blockbuster. Newer immunology and neuroscience products are more than offsetting Humira’s decline.
What to watch:
Watch Skyrizi and Rinvoq growth, neuroscience sales, Botox, pipeline data, Humira erosion, research spending, and updated EPS guidance.
The Takeaway: Buy this if you want strong pharmaceutical cash flow backed by successful product replacement.
The risk is that investors become too dependent on Skyrizi and Rinvoq while older oncology and immunology products keep declining.
Elite Trade Club Insider
$4.2 Million In Insider Selling Just Hit Two Very Different Setups
You’re looking at one steady dividend stock and one beaten-down growth name from the outside, where neither chart screams danger. But Elite Trade Club Insider readers are seeing the cleaner signal first: a major shareholder and a CEO are reducing exposure while the market is still deciding whether stability or recovery comes next.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
This theme works because healthcare does not need one perfect macro outcome.
Johnson & Johnson is the diversified earnings catalyst. UnitedHealth is the managed-care recovery. Intuitive Surgical is the robotic-procedure compounder. Boston Scientific is the cardiovascular device growth name. AbbVie is the pharmaceutical replacement story.
Stay constructive if the earnings confirm procedure growth, drug momentum, and improving insurance economics. But do not treat the sector as automatically safe. Healthcare companies still need clean execution, strong pipelines, cost discipline, and guidance that holds up under scrutiny.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
